Precision Symptom Management: Why Palliative Care Is Poised for a Genomic Revolution
The News That Sparked This Post Tempus AI’s acquisition of OneOme’s pharmacogenomics (PGx) assets is making headlines in precision medicine circles. Most observers see this as an oncology play. They’re not wrong—Tempus has built its reputation on molecular oncology and AI-driven insights. But here’s